NO20025035D0 - Oksadiazolderivater som har anticancer-effekter - Google Patents

Oksadiazolderivater som har anticancer-effekter

Info

Publication number
NO20025035D0
NO20025035D0 NO20025035A NO20025035A NO20025035D0 NO 20025035 D0 NO20025035 D0 NO 20025035D0 NO 20025035 A NO20025035 A NO 20025035A NO 20025035 A NO20025035 A NO 20025035A NO 20025035 D0 NO20025035 D0 NO 20025035D0
Authority
NO
Norway
Prior art keywords
optionally substituted
oxadiazole derivatives
anticancer effects
prodorug
solvate
Prior art date
Application number
NO20025035A
Other languages
English (en)
Other versions
NO324868B1 (no
NO20025035L (no
Inventor
Takayuki Yoshioka
Ryuji Maekawa
Fumihiko Watanabe
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NO20025035D0 publication Critical patent/NO20025035D0/no
Publication of NO20025035L publication Critical patent/NO20025035L/no
Publication of NO324868B1 publication Critical patent/NO324868B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20025035A 2000-04-21 2002-10-18 Oksadiazolderivater som har anticancer-effekt samt farmasoytisk preparat NO324868B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000120234 2000-04-21
PCT/JP2001/003214 WO2001083463A1 (en) 2000-04-21 2001-04-16 Oxadiazole derivatives having anticancer effects

Publications (3)

Publication Number Publication Date
NO20025035D0 true NO20025035D0 (no) 2002-10-18
NO20025035L NO20025035L (no) 2002-12-19
NO324868B1 NO324868B1 (no) 2007-12-17

Family

ID=18631080

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025035A NO324868B1 (no) 2000-04-21 2002-10-18 Oksadiazolderivater som har anticancer-effekt samt farmasoytisk preparat

Country Status (16)

Country Link
US (2) US6720343B2 (no)
EP (1) EP1277744A4 (no)
JP (1) JP3974781B2 (no)
KR (1) KR100542780B1 (no)
CN (1) CN1199956C (no)
AU (2) AU2001246916B2 (no)
BR (1) BR0110211A (no)
CA (1) CA2406685C (no)
HU (1) HUP0300619A3 (no)
MX (1) MXPA02010325A (no)
NO (1) NO324868B1 (no)
PL (1) PL203161B1 (no)
RU (1) RU2275371C2 (no)
TW (1) TWI294877B (no)
WO (1) WO2001083463A1 (no)
ZA (1) ZA200208307B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
WO2005012268A1 (ja) * 2003-07-30 2005-02-10 Shionogi & Co., Ltd. イソオキサゾール環を有するスルホンアミド誘導体
AU2005299851B2 (en) * 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
EP2258700A1 (en) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
KR100783585B1 (ko) 2006-08-22 2007-12-07 한국생명공학연구원 스탯의 활성을 저해하는 옥사다이아졸 우레아 화합물을 유효성분으로 함유하는 암의 예방 또는 치료제
JP5718053B2 (ja) 2007-08-27 2015-05-13 ヘリコン・セラピューティクス・インコーポレーテッド 治療用イソオキサゾール化合物
EP2222667B1 (en) * 2007-12-10 2013-02-20 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as agonists of s1p1/edg1
AR077969A1 (es) 2009-08-31 2011-10-05 Abbott Healthcare Products Bv Derivados de (tio)morfolina comomoduladores de s1p
RU2415845C1 (ru) * 2009-10-14 2011-04-10 Государственное образовательное учреждение высшего профессионального образования "Астраханский государственный университет" (АГУ) Сульфонные производные 2-нитро-2-(3-арил-1,2,4-оксадиазол-5-ил)этана, обладающие противолепрозной и противотуберкулезной активностью
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
CN103450167A (zh) * 2012-05-28 2013-12-18 南京大学 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
BR112022008113A2 (pt) 2019-10-31 2022-07-19 Escape Bio Inc Formas sólidas de um modulador de receptor s1p
CN113264899B (zh) * 2021-04-09 2022-06-14 台州学院 一种1,3,5-噁二嗪类化合物及其制备和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1029541B1 (en) 1997-07-22 2006-03-22 Shionogi & Co., Ltd. Therapeutic or prophylactic agent for glomerulopathy
WO2000015213A1 (en) 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure

Also Published As

Publication number Publication date
NO324868B1 (no) 2007-12-17
PL203161B1 (pl) 2009-08-31
TWI294877B (no) 2008-03-21
HUP0300619A3 (en) 2006-02-28
ZA200208307B (en) 2003-10-15
HUP0300619A2 (hu) 2003-07-28
US6720343B2 (en) 2004-04-13
CA2406685A1 (en) 2002-10-17
CN1436179A (zh) 2003-08-13
MXPA02010325A (es) 2003-04-25
JP3974781B2 (ja) 2007-09-12
AU2001246916B2 (en) 2004-10-07
US20030203940A1 (en) 2003-10-30
KR100542780B1 (ko) 2006-01-11
WO2001083463A1 (en) 2001-11-08
RU2275371C2 (ru) 2006-04-27
AU4691601A (en) 2001-11-12
EP1277744A1 (en) 2003-01-22
PL359415A1 (en) 2004-08-23
EP1277744A4 (en) 2007-07-11
BR0110211A (pt) 2003-06-03
KR20030019357A (ko) 2003-03-06
US20040122066A1 (en) 2004-06-24
NO20025035L (no) 2002-12-19
CN1199956C (zh) 2005-05-04
CA2406685C (en) 2006-10-31

Similar Documents

Publication Publication Date Title
NO20025035D0 (no) Oksadiazolderivater som har anticancer-effekter
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
ATE223378T1 (de) Prolineamid-derivate
DE60107449D1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
DE69820248D1 (de) Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben
CY1111816T1 (el) Παραγωγο θειαδιαζολινης για την θεραπεια του καρκινου
IT1311922B1 (it) Composti farmaceutici.
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
DE60025616D1 (de) Isoindolderivate
NO943895L (no) Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter
DK0570294T3 (da) 2-formylpyridinthiosemicarbazonderivater, deres fremstilling og deres anvendelse som antitumormiddel
AU2003223340A8 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
AU2001269540A1 (en) Serotonin reuptake inhibitors
ATE223411T1 (de) 1-methylcarbapenem-derivate
DE60238847D1 (de) Pyrimidinderivate enthaltendes medikament

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees